A
Amneal Pharmaceuticals, Inc. (AMRX)
NMS – Real Time Price. Currency in USD
12.60
-0.18 (-1.41%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
12.60
-0.18 (-1.41%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | N/A | 2.52 | 1.0 | |
| Quick ratio | N/A | 1.78 | 1.0 | |
| Debt to Equity | N/A | -0.80 | 1.0 | |
| Debt to Assets | N/A | 0.73 | 1.0 | |
| Interest coverage | N/A | -13.90 | 10 | |
| Weighted average score | 2.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 2.21B | 2.39B | 2.79B | 3.02B | 3.05B |
| Gross Profit | 796M | 857M | 1.02B | 1.14B | 857M |
| Operating Income | 200M | 263M | 353M | 423M | 301M |
| Net Income | -130M | -84M | -117M | 72M | 138M |
| EBITDA | 441M | 492M | 589M | 647M | 465M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 4.01 | -10.17 | 2.5 |
| Next quarter | 2.95 | 64.13 | 7.0 |
| Current year | 2.49 | 19.71 | 6.0 |
| Next year | 7.78 | 20.64 | 8.0 |
| Weighted average score | 5.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -11.2 | 122.37 | 28.57 | N/A | 5.5 |
| Y/Y | 3.97 | 539.61 | 28.57 | N/A | 6.3 |
| 3y average | 10.99 | 52.63 | 9.29 | 302.05 | 8.3 |
| 5y average | 8.75 | -250.78 | 8.56 | 154.78 | 5.8 |
| Weighted average score | 6.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $2.7B significantly exceeds cash reserves ($197.7M), raising financial stability concerns
Total current assets $0.0 are just enough to cover Total current liabilities $0.0, indicating tight liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
The company has no interest-bearing debt, showcasing excellent financial strength